Axiom Investors LLC DE Decreases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Axiom Investors LLC DE cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,900 shares of the specialty pharmaceutical company’s stock after selling 1,695 shares during the quarter. Axiom Investors LLC DE’s holdings in Supernus Pharmaceuticals were worth $718,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 1.1% during the third quarter. Vanguard Group Inc. now owns 5,680,242 shares of the specialty pharmaceutical company’s stock worth $192,276,000 after buying an additional 59,794 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Supernus Pharmaceuticals by 2.2% in the 1st quarter. Macquarie Group Ltd. now owns 2,474,069 shares of the specialty pharmaceutical company’s stock worth $89,636,000 after purchasing an additional 53,535 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 1.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,430,916 shares of the specialty pharmaceutical company’s stock worth $73,073,000 after purchasing an additional 39,650 shares in the last quarter. Stephens Investment Management Group LLC lifted its holdings in Supernus Pharmaceuticals by 3.6% in the 1st quarter. Stephens Investment Management Group LLC now owns 1,662,262 shares of the specialty pharmaceutical company’s stock valued at $60,224,000 after acquiring an additional 57,493 shares during the last quarter. Finally, GW&K Investment Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 0.7% during the first quarter. GW&K Investment Management LLC now owns 1,416,104 shares of the specialty pharmaceutical company’s stock valued at $51,306,000 after acquiring an additional 9,576 shares during the period.

Supernus Pharmaceuticals Stock Down 0.4 %

SUPN stock opened at $27.31 on Tuesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $21.99 and a twelve month high of $42.09. The company has a market cap of $1.49 billion, a price-to-earnings ratio of 66.61 and a beta of 1.08. The business has a 50 day moving average price of $26.46 and a two-hundred day moving average price of $30.21.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.42). The business had revenue of $153.88 million during the quarter, compared to the consensus estimate of $143.39 million. Supernus Pharmaceuticals had a net margin of 4.20% and a return on equity of 2.82%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 EPS. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.59 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Frederick M. Hudson sold 9,093 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $28.50, for a total value of $259,150.50. Following the sale, the director now directly owns 33,231 shares in the company, valued at $947,083.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Frederick M. Hudson sold 9,093 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.50, for a total value of $259,150.50. Following the completion of the sale, the director now owns 33,231 shares of the company’s stock, valued at approximately $947,083.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Tami Tillotson Martin sold 8,100 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $32.00, for a total value of $259,200.00. Following the completion of the transaction, the vice president now owns 85,249 shares in the company, valued at approximately $2,727,968. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,438 shares of company stock valued at $711,789. 8.76% of the stock is currently owned by insiders.

Analyst Ratings Changes

SUPN has been the subject of several analyst reports. Piper Sandler lifted their price objective on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an “overweight” rating in a research note on Thursday, November 9th. StockNews.com lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.